Narrative review / 2011
Most evidence suggests hyperhomocysteinemia is a risk factor for Alzheimer's disease onset, though findings remain conflicting.
This review summarizes epidemiological investigations, including observational studies and randomized controlled clinical trials, evaluating the relationship between hyperhomocysteinemia and Alzheimer's disease. While patients with histologically confirmed Alzheimer's disease show higher plasma homocysteine levels than controls, conflicting findings persist across studies. The authors also review in vivo and in vitro evidence on mechanisms through which hyperhomocysteinemia might influence Alzheimer's disease development.
Shows an association, not proof of cause and effect.
- Study type
- Narrative review
- Who was studied
- Patients with Alzheimer's disease and control populations from published studies
- What was measured
- Alzheimer's disease onset and potential biological mechanisms related to hyperhomocysteinemia
THE PAPER
Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?
Zhuo JM, Wang H, Praticò D. Trends Pharmacol Sci, 2011.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.